Clinical trials: Astrocytoma, Grade IV
c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
The study assessed the safety and the dose of the combination of INC280 and buparlisib (BKM120), as well as the anti-tumor activity of the combination, in patients with recurrent glioblastoma with PTEN mutations, homozygous…
- Trial name
- NCT01870726
- Testing
- INC280, Buparlisib
- Where
- 13 sites in United States, Germany and 3 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma
Oral Gallium Maltolate for Recurrent Glioblastoma
This is a Phase 0 investigational study to assess the central nervous system penetration and tumoral concentration of gallium in patients with recurrent glioblastoma administered with preoperative gallium maltolate.
- Trial name
- NCT07515924
- Testing
- Gallium Maltolate, Surgical Intervention
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Medical College of Wisconsin
Glioblastoma
Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma
This is a prospective, randomized, open-label, multicenter phase II study. Newly-diagnosed primary glioblastoma patients who have undergone maximal safe resection or biopsy and completed standard concurrent chemoradiotherapy will…
- Trial name
- NCT07789379
- Testing
- Adebrelimab, Temozolomide, Procedure:Hyperbaric Oxygen Therapy
- Volunteers
- 94 people
- Sponsor
- Wei Jiang
Recurrent Glioblastoma
Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma
This multicenter, open-label, externally controlled clinical study is designed to evaluate the safety and efficacy of CHANK-101, an autologous natural killer (NK) cell therapy, in patients with recurrent glioblastoma.
- Trial name
- NCT07831161
- Testing
- CHANK-101
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Dong-A University Hospital
Glioblastoma Multiforme
Deuterium Metabolic Imaging to Assess Radiotherapy Changes in Glioblastoma Multiforme
This is a feasibility single arm study designed for obtaining early data for optimization and evaluation of the clinical potential for a new MR technique using deuterated glucose.
- Trial name
- NCT05908669
- Testing
- Deuterium metabolic imaging
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University of Aarhus
Glioblastoma
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
This phase 0 trial studies ixazomib citrate in treating patients with glioblastoma that has spread or returned after period of improvement who are planning to undergo surgery.
- Trial name
- NCT02630030
- Testing
- Ixazomib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Glioblastoma
89Zr-RO5323441 PET Imaging in Glioblastoma
The research the investigators propose is a molecular imaging study of RO5323441, an antibody against placental growth factor (PlGF) in patients with recurrent GBM treated with bevacizumab, a drug against vascular endothelial…
- Trial name
- NCT01622764
- Testing
- Molecular imaging with 89Zr-RO5323441
- Where
- Netherlands
- Sponsor
- University Medical Center Groningen
Hepatocellular Carcinoma, Glioblastoma
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
- Conditions
- Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer
- Trial name
- NCT05131763
- Testing
- NKG2D-based CAR T-cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Fudan University
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastom WHO Grade 4
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.
- Trial name
- NCT07520214
- Testing
- mRNA vaccine: GV-907、GV-108
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Neurosurgical Institute
Glioblastoma
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
This phase I trial studies the side effects of nivolumab, BMS-986205, and standard radiation therapy with or without temozolomide in treating patients with new diagnosed glioblastoma.
- Trial name
- NCT04047706
- Testing
- IDO1 Inhibitor BMS-986205 25mg, Nivolumab, Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Northwestern University
Glioblastoma
Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy
Glioblastoma is the most aggressive primary brain tumor due to its highly infiltrative growth pattern, strong proliferative potential, and multiple mechanisms of resistance to treatment .
- Trial name
- NCT07141732
- Testing
- Resection of newly diagnosed glioblastoma combined with intraoperative balloon electronic brachytherapy using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Joint Stock Company European Medical Centre
Meningioma, Glioblastoma
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
- Conditions
- Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer
- Trial name
- NCT07493447
- Testing
- Panitumumab-IRDye800
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eben Rosenthal
Glioblastoma
Tumor Electric Fields Treatment System for Glioblastoma
This early phase I trial will investigate the safety and feasibility of applying the Tumor Electric Fields Treatment System to subjects with recurrent glioblastoma.
- Trial name
- NCT04417933
- Testing
- Tumor Electric Fields Treatment System
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xiangya Hospital of Central South University
Glioblastoma (GBM)
Sonodynamic-Chemoradiotherapy Integration in Glioblastoma
This Phase II trial tests if sonodynamic therapy (SDT)-a non-invasive treatment using ultrasound to activate a cancer-killing drug-improves outcomes for newly diagnosed glioblastoma patients.
- Trial name
- NCT07130149
- Testing
- Sonodynamic Therapy (SDT), Standard Treatment
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Yingjuan Zheng
Glioblastoma Multiforme
Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)
Blood samples will be obtained from newly diagnosed GBM patients treated with combined radiotherapy (RT), temozolomide (TMZ) and bevacizumab (BEV) at specific time points.
- Trial name
- NCT01091792
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Glioblastoma, Adult
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
The purpose of this study is to test the side effects and efficacy of using Laser Interstitial Thermotherapy (LITT) combined with Pembrolizumab.
- Trial name
- NCT03277638
- Testing
- Pembrolizumab at 7 days prior, Pembrolizumab at 14 days post, Pembrolizumab at 35 days post
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Case Comprehensive Cancer Center
Glioblastoma Multiforme
Chlorpromazine and Standard of Care in Glioblastoma
This is a phase 1 study investigating the re-purposing of chlorpromazine, combined with temozolomide and radiation in the treatment of newly diagnosed glioblastoma multiforme.
- Trial name
- NCT05190315
- Testing
- Chlorpromazine, Temozolomide, Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mohammed Milhem
Glioblastoma
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
The purpose of this study is to test how safe and effective treatment with the combination of Avelumab and radiation is for IDH mutant gliomas that have transformed to glioblastoma after chemotherapy.
- Trial name
- NCT02968940
- Testing
- Avelumab, Hypofractionated radiation therapy (HFRT)
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- NYU Langone Health
Glioblastoma, Gliosarcoma
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
This is a phase II study of Bevacizumab plus Temodar and Tarceva in patients with non-progressive glioblastoma or gliosarcoma. Patients must have stable disease immediately following a standard course of up-front radiotherapy and…
- Trial name
- AVF4120s (NCT00525525)
- Testing
- Bevacizumab, Tarceva, Temozolomide
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Francisco
Glioblastoma, Surgery
Neoadjuvant Chemoradiation for Resectable Glioblastoma
Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the…
- Conditions
- Glioblastoma, Surgery, High Grade Glioma
- Trial name
- NeoGlio (NCT04209790)
- Testing
- Neoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Geisinger Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.